ASSESSMENT OF THE NEW PROLIFERATION MARKER MIB1 IN BREAST-CARCINOMA USING IMAGE-ANALYSIS - ASSOCIATIONS WITH OTHER PROGNOSTIC FACTORS AND SURVIVAL

The 'growth fraction' of tumours can now be assessed on paraffin sections of tissues using the monoclonal antibody MIBI by a microwave antigen retrieval technique. The MIBI labelling index was studied using a CAS 200 image analyser in 177 tumours from women with primary operable breast carcinoma in whom long-term follow-up data were known. Statistical analysis showed a strong association between the MIBI labelling index and histological grade (P <0.001), tumour size (P = 0.002), tumour type (P <0.001) and also patient survival (P <0.001). No association with lymph node stage (P = 0.59), local (P = 0.974) or regional recurrence (P = 0.185), the presence or absence of distant metastases (P = 0.418), patient age (P = 0.309), menopausal status (P = 0.181) or oestrogen receptor status (P = 0.401) was found in this group of patients. In multivariate analysis for survival, when histological grade, lymph node stage and tumour size were included as well as the MIB1 labelling index, each was found to be of independent significance. If histological grade was not included, MIB1 replaced it as the most important variable predicting for survival in. this group of patients. The results suggest that the tumour growth fraction, as assessed by the MIB1 labelling index, is an important predictor of survival.